William D. Schwieterman

William D. Schwieterman, M.D., is President and Chief Executive Officer of Mateon Therapeutics, Inc. Dr. Schwieterman has assembled a world-class management team and is working to transform the organization into a leading oncology company. Dr. Schwieterman is a rheumatologist and board-certified internist with more than 15 years of executive, regulatory and drug development experience in the biopharmaceutical industry. He has been an independent consultant to multiple biotech and pharmaceutical clients where he helped them create their regulatory and clinical development strategies. Before joining Mateon, he was an employee of Perceptive Advisors, LLC, a hedge fund based in New York, New York. Dr. Schwieterman was also the Chief Medical Officer of Chelsea Therapeutics, Inc., a publicly traded biopharmaceutical development company, where he led the clinical development team toward the approval of droxidopa — Northera — for the treatment of symptomatic neurogenic orthostatic hypotension, a nonmotor symptom, associated with Parkinson’s disease and other neurogenerative diseases. Dr. Schwieterman was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the Food and Drug Administration, or FDA. In these capacities and others, Dr. Schwieterman spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a large number of different types of molecules. Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati.